Navigation Links
Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Date:9/20/2011

HOBOKEN, N.J. and PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

NKP-1339 Phase I Interim DataThe Phase I trial is conducted in patients with metastatic solid tumors resistant to standard therapies. Previous to enrollment in the trial, all patients had received multiple standard therapies and exhibited disease progression on their last treatment. Of the first 24 patients enrolled, six patients (25%) exhibited anti-tumor activity, demonstrated by disease stability and/or tumor regression for at least 12 weeks.

Of the responding six patients, one patient with carcinoid tumor, a non-pancreatic neuroendocrine tumor (non-pNET), has tumor regression and continues on NKP-1339 therapy for more than 70 weeks. The five other patients have experienced stable disease of up to 24 weeks with NKP-1339 treatment. These patients have the following tumor types: one gastrinoma non-pNET, one colorectal cancer, two non-small cell lung cancers and one cancer of unknown primary.

NKP-1339 treatment has been well tolerated to date with mild manageable side effects. The most common drug-related side effects are grade 1-2 fever and mild flu-like symptoms, which can be prevented with standard medications. The maximum tolerated dose has not been reached and NKP-1339 dose escalation continues.

The trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute (TGen), and Dr. Howard Burris, Director of Drug Development at the Sarah Cannon Research Institute (SCRI).

"We need new treatments for patients with non-pNET. The NKP-1339 anti-tumor activity observed in these two non-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
3. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
6. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
7. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
8. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
9. Pharmasset to Present at Two Upcoming Conferences
10. MDC Partners Launches Integrated Healthcare Marketing Platform With Acquisition of Majority Stake in Concentric Pharma Advertising
11. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... LATHAM, N.Y. , Feb. 26, 2015 ... support more research to fight heart disease.  Nevertheless, year ... rely on ElectroCardioGrams (EKG) as the first test to ... whether they have chest pain or not, even though ... This occurs despite the fact that doctors know, (while ...
(Date:2/26/2015)... SAN JOSE, Calif. , Feb. 26, 2015 /PRNewswire/ ... Dickinson and Company) (NYSE: BDX ), ... Research, an innovative company focused on enabling high-resolution ... promoting their unique solutions for highly multiplexed cell ... The companies are promoting BD,s powerful BD FACS™ ...
(Date:2/26/2015)... -- The report, "Bottled Water Processing ... Blow molder, Shrink wrapper), Technology (RO, UF, MF, ... Region - Trends & Forecasts to 2019", published ... processing market with analyses and projection of the ... also identifies the driving and restraining factors for ...
Breaking Medicine Technology:National Heart Health Month In February 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4
... Pharmaceuticals (Nasdaq: ENDP ) announced today that ... novel treatments for pain and to discover potential treatments ... University , is based upon a new pain-drug-delivery technique ... Richard J. Kitz Professor of Anaesthesia Research at Massachusetts ...
... Ariz., Feb. 10 Recent clinical data show that ... one repeat injection. Restylane (R) is ... duration claim. These data were generated in a controlled, ... two different retreatment schedules, 4.5 months or 9 months, after ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 3Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection 2
(Date:2/27/2015)... February 27, 2015 Several studies showing ... heart failure have made headline news recently. However, all ... research appearing in this month’s STEM CELLS Translational Medicine ... in treating children with congenital heart diseases that can ... by researchers at the Mayo Clinic in Rochester, Minn., ...
(Date:2/27/2015)... Ticket Down announces that Ed Sheeran ... of 2015. Tickets for his tour have been a ... record pace. , Ed Sheeran 2015 Tour Dates: ... Wednesday, May 6, 2015 , 5/7/15, Ed Sheeran Tickets, Grand ... 2015 , 5/9/15, Ed Sheeran Tickets, Tulsa, OK BOK Center, ...
(Date:2/27/2015)... Burien Nursing and Rehabilitation Center was ... with the Facility of the Year award. This award ... quality of care / satisfaction, census development, employee satisfaction ... to attend the awards banquet held in Dana Point, ... receive this award on behalf of our team at ...
(Date:2/27/2015)... 2015 RDI-Engineering will be hosting an ... event on March 14, at Moreno Valley College. The ... how to use engineering software and tools, and a ... by Moreno Valley College’s Upward Bound Math and Science ... in hopes to encourage students to seek educational and ...
(Date:2/27/2015)... Vegas, NV (PRWEB) February 27, 2015 Leading ... bring health and wellness to Americans nationwide. Each month they ... aspects of health and wellness, and healthy living. In the ... Week. National Sleep Awareness Week starts by bringing ... Daylight Savings. This year Sleep Awareness Week will start on ...
Breaking Medicine News(10 mins):Health News:Study Shows Stem Cells Have Potential to Help Kids’ Hearts, Too 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 3Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 4Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:Emassagechair Wants Shoppers to Think About the Benefits of Massage During National Sleep Awareness Week 2Health News:Emassagechair Wants Shoppers to Think About the Benefits of Massage During National Sleep Awareness Week 3
... /Xinhua-PRNewswire/ -- Simcere,Pharmaceutical Group (NYSE: SCR ), ... and manufacturer of the patented,anti-cancer biotech product Endu ... Carret & Co.,s Fourth Investor Tour of China,being ... April 4, 2008 in Beijing,Shenzhen and Shanghai., ...
... Beef is Eligible to Carry New Consumer Label, ... for the,implementation of E. coli-safeguards, that include new ... cattle, have been,adopted and implemented by VeriPrime, Inc., ... Beef Technical Advisory Council., (Logo: http://www.newscom.com/cgi-bin/prnh/20080401/AQTU070LOGO ...
... Fork, Care and Prevention, WICHITA, Kan., April ... and higher new safety standards, including protections,against E. ... leading farmers and,ranchers behind the food safety seal, ... Citing growing consumer concern over food safety ...
... 1, 2008 Natural,Nutrition, Inc. (OTC Bulletin Board: ... InterACTIVE Nutrition, Inc. (INII) achieved record unaudited,sales of ... EBITDA for the,year ended December 31, 2007., ... are pleased to,report record results for our first ...
... China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ) ... the research, development, manufacture,and marketing of pharmaceutical, nutritional ... China ("PRC"), announced its financial,results for full year ... 2007 Highlights -- Net sales totaled ...
... American physicians opinions on health-care financing has found that ... national health insurance while only 32 percent oppose it. ... 2002 found 49 percent of physicians supporting national health ... The 2007 survey results demonstrate a significant change in ...
Cached Medicine News:Health News:Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.'s Fourth Investor Tour of China 2Health News:VeriPrime Approves New Best Practices for Beef Production 2Health News:VeriPrime Approves New Best Practices for Beef Production 3Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 2Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 3Health News:Natural Nutrition Subsidiary Reports Record Year-End Revenue and EBITDA 2Health News:China Shenghuo Reports Full Year 2007 Financial Results 2Health News:China Shenghuo Reports Full Year 2007 Financial Results 3Health News:China Shenghuo Reports Full Year 2007 Financial Results 4Health News:China Shenghuo Reports Full Year 2007 Financial Results 5Health News:China Shenghuo Reports Full Year 2007 Financial Results 6Health News:China Shenghuo Reports Full Year 2007 Financial Results 7Health News:China Shenghuo Reports Full Year 2007 Financial Results 8Health News:China Shenghuo Reports Full Year 2007 Financial Results 9Health News:China Shenghuo Reports Full Year 2007 Financial Results 10Health News:China Shenghuo Reports Full Year 2007 Financial Results 11Health News:China Shenghuo Reports Full Year 2007 Financial Results 12Health News:China Shenghuo Reports Full Year 2007 Financial Results 13Health News:Indiana University study finds majority of US physicians favor national health insurance 2
Flexible rake retractor, 3 blunt prongs....
Rees bayonet forceps, standard, 5-1/2", TC....
... Implants, designed to accept rigid ... with an excellent reconstructive option ... floor blowout defects. Each design ... of one or more rigid ...
... Medpor Midface Rim is designed ... concavities of the midface, including ... malar. When positioned in the ... Medpor Midface Rim implant aids ...
Medicine Products: